M. D. Anderson Cancer Center - News Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Science Names Cancer Immunotherapy its 2013 Breakthrough of the Year
Detect. Destroy. Remember. The mantra of the immune system's relentless campaign against infectious invaders and the body's own abnormal cells finally is applying to cancer in meaningful ways.   (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 20, 2013 Category: Cancer & Oncology Source Type: news

Younger, early breast cancer patients often undergo unnecessary staging, imaging procedures at time of diagnosis
More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures - including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 17, 2013 Category: Cancer & Oncology Source Type: news

MD Anderson researcher Jim Allison wins Breakthrough Prize for his innovative cancer immunology research
Basic science research that exposed vital details of cancer's defense against the immune system, revealing an entirely new way to combat these diseases, has earned Jim Allison, Ph.D., a Breakthrough Prize in Life Sciences. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 17, 2013 Category: Cancer & Oncology Source Type: news

Affiliation between Orlando Health and The University of Texas MD Anderson Cancer Center set to expire
After working together for more than 23 years to accomplish their joint goal of raising the quality of cancer care in Central Florida, Orlando Health and The University of Texas MD Anderson Cancer Center in Houston have decided not to renew their business relationship when the contract expires. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 17, 2013 Category: Cancer & Oncology Source Type: news

Ibrutinib and rituximab trigger 95 percent response rate among CLL patients
Nearly all of the high-risk chronic lymphocytic leukemia patients in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib and the antibody rituximab, researchers reported today, at the 55th Annual Meeting of the American Society of Hematology. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 12, 2013 Category: Cancer & Oncology Source Type: news

Targeted antibody, immune checkpoint blocker rein in follicular lymphoma
One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response. Together, they put half of the patients with relapsed follicular lymphoma into complete remission in a phase II clinical trial at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 12, 2013 Category: Cancer & Oncology Source Type: news

MD Anderson physician receives Susan G. Komen's highest honor for excellence in breast cancer research
Presented at the 36th annual CTRC-AACR San Antonio Breast Cancer Symposium, the award recognizes Mills extensive contributions to understanding the molecular biology and pathology of breast cancer in his nearly three decade career as a physician-scientist.  (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 12, 2013 Category: Cancer & Oncology Source Type: news

Cancer-promoting protein is vital to safe division of tumor cells
Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of  brain tumors. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 9, 2013 Category: Cancer & Oncology Source Type: news

Clinical trials use Sleeping Beauty gene transfer to create CAR T cells
The first clinical trials using the Sleeping Beauty gene transfer system to customize immune system T cells to attack specific types of leukemia and lymphoma indicate the approach to be safe and feasible, investigators reported at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 9, 2013 Category: Cancer & Oncology Source Type: news

Ibrutinib suppression of chronic lymphocytic leukemia endures in second year
The targeted therapy ibrutinib continues to stifle relapsed or resistant chronic lymphocytic leukemia for patients in an extended clinical trial while treatment side effects decline in frequency and severity over time, researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 9, 2013 Category: Cancer & Oncology Source Type: news

MD Anderson researchers identify a rescuer for vital tumor-suppressor
A protector for PTEN, a tumor-thwarting protein often missing in cancer cells, has emerged from research led by scientists at The University of Texas MD Anderson Cancer Center published online at Nature Cell Biology this week.    (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 27, 2013 Category: Cancer & Oncology Source Type: news

Four from MD Anderson named Fellows in AAAS
A basic scientist, a biostatistician and two researchers who connect scientific findings with the clinic are the newest Fellows elected to the American Association for the Advancement of Science from The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 25, 2013 Category: Cancer & Oncology Source Type: news

Combination therapy not necessary to achieve remission in breast cancer patients with HER-2-positive disease
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 14, 2013 Category: Cancer & Oncology Source Type: news

MD Anderson to honor former Secretary of State James A. Baker, III during A Conversation With a Living Legend® at the Kennedy Center
Former Secretary of State James A. Baker, III and his career of public service will be the focus of A Conversation With a Living Legend® benefiting The University of Texas MD Anderson Cancer Center in Washington, D.C., Nov. 12 at the John F. Kennedy Center for the Performing Arts. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 8, 2013 Category: Cancer & Oncology Source Type: news

Tobacco Myths Persist 50 Years After the US Surgeon General First Warned Americans of the Dangers of Smoking
MD Anderson experts debunk myths, share new facts and resources to address this persistent health issue (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 7, 2013 Category: Cancer & Oncology Source Type: news